Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiye Tongmai Capsule is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Jilin Tianyao Technology Co., Ltd. for the treatment of cerebrovascular and cardiovascular disorders. The primary active ingredient is the total saponins of *Panax notoginseng* (PNS), which includes various ginsenosides and notoginsenosides. It is clinically indicated for stroke, cerebral infarction, hemiplegia, and angina pectoris, particularly when these conditions are associated with the TCM syndrome of blood stasis. The drug works by promoting blood circulation, reducing blood viscosity, and inhibiting platelet aggregation. Additionally, it exhibits neuroprotective properties by reducing oxidative stress and inflammatory responses in brain tissue following ischemic events, thereby improving microcirculation and supporting functional recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiye Tongmai Capsule.